Updates are available Erratum dated 2017-09-07
Click to view Erratum: https://doi.org/10.1007/s10549-017-4482-3
-
Authors
Cortés, Javier
Rugo, Hope S.
Awada, Ahmad
Twelves, Chris
Perez, Edith A.
Im, Seock–Ah
Gómez-Pardo, Patricia
Schwartzberg, Lee S.
Diéras, Veronique
Yardley, Denise A.
Potter, David A.
Mailliez, Audrey
Moreno-Aspitia, Alvaro
Ahn, Jin-Seok
Zhao, Carol
Hoch, Ute
Tagliaferri, Mary
Hannah, Alison L.
O’Shaughnessy, Joyce http://orcid.org/0000-0001-6764-2807
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01492101 at ClinicalTrials.govDocuments that mention this clinical trial
Emerging PEGylated non-biologic drugs
https://doi.org/10.1080/14728214.2019.1604684
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
https://doi.org/10.1007/s10549-017-4304-7
-
Funding
Funding for this research was provided by:
Nektar Therapeutics
- License Information
-
More Information
Article History
Received: 12 May 2017
Accepted: 16 May 2017
First Online: 13 June 2017
Change Date: 7 September 2017
Change Type: Erratum
Change Details: An erratum to this article has been published.
Compliance with ethical standards
:
: JC: advisor: Celgene, Roche; speaker: Celgene, Roche, Eisai, Novartis; partner and stockholder: MedSIR. HSR: research support to UC Regents from Eisai and from Nektar for this trial. AA: advisor: Nektar Therapeutics, Roche, Bayer, Pfizer. CJT: advisor: Nektar Therapeutics. VD: advisor: Roche, Novartis, Pfizer, Nektar, Eisai, Lilly; speaker: Roche, Pfizer, Novartis. CZ, MT, and UH: paid employees of Nektar Therapeutics. ALH: consultant, Nektar Therapeutics. JO: advisor: Nektar Therapeutics. EAP, S-AI, LSS, PG-P, DAY, DAP, AM, AM-A, and J-SA declare no conflicts of interest.
